Hepion Pharmaceuticals, Inc.
corporate_fare Company Profile
Hepion Pharmaceuticals, Inc. (OTC:HEPA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for HEPA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for HEPA spans 8-K, 10-K.
Recent high-impact activity:
- FDA Backs GV104 Prophylaxis Path After Simulation Prevents All Fentanyl Cardiac Arrests
- FDA Backs 505(b)(2) Path for GV104 in Gambling Disorder, IND Targeted for 2027
- Hepion Closes Gravitas Acquisition, Gains FDA-Endorsed Opioid Countermeasure
- Hepion Pharmaceuticals Finalizes CEO Separation Agreement, Discloses $255K Payout Amidst Going Concern Warning
- Hepion Pharmaceuticals CEO Resigns Amidst Financial Distress; Interim CEO and New Directors Appointed
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 15 shares in HEPA as of the October 30, 2026 settlement, a 99.6% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 19.1% of HEPA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.